RENB icon

Renovaro

0.3732 USD
+0.0004
0.11%
At close Apr 25, 4:00 PM EDT
After hours
0.3727
-0.0005
0.13%
1 day
0.11%
5 days
10.12%
1 month
-43.88%
3 months
-54.69%
6 months
-26.97%
Year to date
-51.09%
1 year
-78.05%
5 years
-90.67%
10 years
-95.56%
 

About: Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Employees: 25

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

371% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 7

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

159% more capital invested

Capital invested by funds: $7.13M [Q3] → $18.5M (+$11.4M) [Q4]

16% more funds holding

Funds holding: 50 [Q3] → 58 (+8) [Q4]

3.93% more ownership

Funds ownership: 10.01% [Q3] → 13.94% (+3.93%) [Q4]

15% less call options, than puts

Call options by funds: $35K | Put options by funds: $41K

Research analyst outlook

We haven’t received any recent analyst ratings for RENB.

Financial journalist opinion

Based on 3 articles about RENB published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing (“HPC”) built on the latest platform to accelerate biomarker discovery and next-generation diagnostics.
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Neutral
GlobeNewsWire
2 weeks ago
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo validation and drug discovery to Renovaro's AI powered biomarker and diagnostic platform.
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Neutral
GlobeNewsWire
3 weeks ago
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. (“POI”) dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025 (collectively, the “Binding Agreements”).
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Neutral
GlobeNewsWire
1 month ago
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro's Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has advanced the first tranche of financing to Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. By adding Predictive's AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data to Renovaro's multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise, the combined company will be positioned to commercialize its drug discovery and diagnostic platforms.
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Neutral
GlobeNewsWire
1 month ago
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Neutral
GlobeNewsWire
1 month ago
Renovaro Announces $15 million in Equity Committed
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term. David Weinstein, Chief Executive Officer of Renovaro, commented, “We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.
Renovaro Announces $15 million in Equity Committed
Neutral
Business Wire
3 months ago
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive.
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Neutral
GlobeNewsWire
3 months ago
Renovaro Issues Shareholder Letter and Provides Corporate Update
Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025.
Renovaro Issues Shareholder Letter and Provides Corporate Update
Neutral
GlobeNewsWire
3 months ago
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial leadership roles.
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Neutral
GlobeNewsWire
3 months ago
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology's AI-driven multi-omic drug discovery platform with Renovaro's AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction. David Weinstein, Chief Executive Officer of Renovaro, commented, “Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring.
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Charts implemented using Lightweight Charts™